WO2015074606A1 - 紫杉烷类化合物、其制备方法和用途 - Google Patents
紫杉烷类化合物、其制备方法和用途 Download PDFInfo
- Publication number
- WO2015074606A1 WO2015074606A1 PCT/CN2014/091911 CN2014091911W WO2015074606A1 WO 2015074606 A1 WO2015074606 A1 WO 2015074606A1 CN 2014091911 W CN2014091911 W CN 2014091911W WO 2015074606 A1 WO2015074606 A1 WO 2015074606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- reaction
- pcmi
- taxane
- Prior art date
Links
- QJKKYFDVMOHASV-SQWONWGRSA-N CC(C)([C@@]([C@H]1O2)([C@H](C(C)([C@]3([C@H](C[C@H]4OC5)O)[O]=C3[C@@H]3OC)[C@@]45[O](C(C)=O)I)OC(c4ccccc4)=O)OC2=O)C3=C(C)[C@H]1OC Chemical compound CC(C)([C@@]([C@H]1O2)([C@H](C(C)([C@]3([C@H](C[C@H]4OC5)O)[O]=C3[C@@H]3OC)[C@@]45[O](C(C)=O)I)OC(c4ccccc4)=O)OC2=O)C3=C(C)[C@H]1OC QJKKYFDVMOHASV-SQWONWGRSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Definitions
- the invention belongs to the field of medicinal chemistry and relates to a novel compound, in particular to a taxane compound.
- the present invention also relates to a process for the preparation of the taxane compound and its use as an active ingredient in the preparation of an oral antitumor drug.
- Paclitaxel (PTX) the structure is as follows:
- Paclitaxel is an anti-tumor active substance extracted from the bark of the Taxus genus Taxus brevifolia in 1971. It has a unique anti-cancer mechanism and has a definite therapeutic effect on various cancers.
- paclitaxel is usually administered intravenously, but because paclitaxel is extremely poor in water solubility, it is dissolved in a mixed solvent of polyoxyethylene castor oil Chremophor EL and ethanol (1:1, v/v). It has become an injection of paclitaxel, and the market name is Taxol or Paxene.
- paclitaxel Although the clinical application of paclitaxel has achieved great success, it has also been restricted by many factors: (1) Firstly, the toxic side effects of paclitaxel itself on normal tissue cells and the inability to pass the blood-brain barrier, etc., include: Dose-limiting toxicity and myelosuppression (clinically required to be treated with growth factors); (2) With the application of Chremophor EL, the following problems are: severe allergic reactions, primary hyperlipidemia, central nervous system toxicity And changes in paclitaxel pharmacokinetics [ten Tije AJ, et al, Clin Pharmacokinet 42, 655-685, 2003; H. Gelderblom, et al, Eur. J.
- the present inventors devoted themselves to the study of 14 ⁇ -OH-DAB derivatives, and finally found a series of novel compounds capable of improving oral bioavailability.
- the results of pharmacological experiments prove that a series of taxane derivatives containing 1,14-carbonate baccatin III synthesized by the present invention are different from the prior art for various people.
- the cancer cell strain has strong cytotoxic activity and has a broad-spectrum anti-tumor effect.
- the present invention provides a taxane-like compound having the structure of the following formula I:
- R 1 is -COR 6 , -COOR 6 , -CONR 7a R 7b ;
- R 2 is C1-C6 alkyl, C1-C6 alkenyl, substituted hydrocarbyl, heterocyclyl, aryl or substituted aryl;
- R 3 is -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b ;
- R 4 is -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b , H, OH;
- R 6 is a C1-C6 alkyl group, a C1-C6 alkenyl group, a C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and each of R 7a and R 7b is a hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group.
- the invention also provides a preparation method of the taxane compound of the invention:
- the preparation method of the taxane compound of the present invention comprises:
- Step 1 Synthesis of taxane-based core fraction: 10-deacetylbaccatin III is used as a raw material. First, the C7 and C10 hydroxyl groups are selectively protected by a substituent, and then the C13 hydroxyl group is oxidized to a ketone carbonyl group.
- N-(sulfonyl)oxaziridines highly stereoselectively introduces a hydroxyl group in the ⁇ configuration at the C14 position, in N,N'-carbonyldiimidazole (CDI)
- CDI N,N'-carbonyldiimidazole
- the 1,14-carbonate structure is formed by the action of the CBS reduction method, and the C13 ketone carbonyl group is highly stereoselectively reduced to the hydroxyl group of the ⁇ configuration to obtain the taxane core moiety.
- Step 2 Synthesis of 5-membered ring oxazolidine acid side chain precursor: After a series of upper protecting groups, addition condensation, acid hydrolysis, aldol condensation, catalytic hydrogenation, etc., a 5-membered oxazolidine is prepared. Acid side chain precursor;
- Step 3 Synthesis of a taxane derivative: the five-membered cyclic oxazolidine acid side chain precursor is esterified and docked with the taxane-based parent core portion, and subjected to acid hydrolysis and deprotection to form a series of Taxane derivatives.
- the preparation method of the taxane compound of the present invention comprises:
- Step 1 Synthesis of the taxane core moiety: 10-deacetylbaccatin III was used as the starting material.
- the C7 and C10 hydroxyl groups were selectively protected by a substituent, and then the C13 hydroxyl group was oxidized to a ketone carbonyl group.
- N-(sulfonyl)oxaxime is used to introduce a hydroxyl group in the ⁇ configuration at a C14 position with high stereoselectivity, and a 1,14-carbonate structure is formed by the action of N,N'-carbonyldiimidazole.
- CBS reduction method the C13 ketone carbonyl group is highly stereoselectively reduced to the hydroxyl group of the ⁇ configuration, and the taxane core moiety is obtained;
- Step 2 Synthesis of 5-membered ring oxazolidine acid side chain precursor: using glycolic acid as raw material, followed by benzyl protection and Boc-based protection to form Boc-protected benzyl glycolate; with different substituted aldehydes and (S R )-tert-butylsulfinamide is condensed to form the corresponding enamine compound; Boc-protected benzyl glycolate and enamine compound are added under the action of lithium salt, and then acid hydrolysis to obtain a chiral intermediate The intermediate is subjected to an aldol condensation reaction with 1,1'-(dimethoxymethyl)p-methoxybenzene under the catalytic action of pyridinium p-toluenesulfonate, and the amino group in the resulting compound is different. The substituent is substituted, and finally subjected to catalytic hydrogenation to obtain a five-membered cyclic oxazolidine acid side chain precursor;
- Step 3 Synthesis of taxane derivatives: esterification of the five-membered ring oxazolidine side chain precursor with the taxane core moiety, and deprotection by acid hydrolysis to form a series of taxanes derivative.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof as defined above as an active ingredient, and a compound of the formula (I) of the present invention, a pharmaceutically acceptable salt thereof or The use of a pharmaceutical composition whose solvate is an active ingredient for the preparation of an oral antitumor drug.
- the CBS reduction method is selected, and the CBS reduction method can be highly stereoselectively reduced to obtain the C13 position compared to the conventional reduction method using metal borohydride.
- the hydroxyl group in the ⁇ configuration has an ee value of >99.9% and a yield of up to 90% or more.
- the present invention synthesizes a series of taxane derivatives containing a 1,14-carbonate baccatin III structure by simultaneously changing the substituents of paclitaxel C7, C10, C14, C3'N and C3' sites.
- cytotoxic activity tests on various cancer cell lines showed good anti-tumor activity, and the Caco-2 monolayer cell membrane transmembrane transport assay was used to in vitro oral bioavailability of such taxane derivatives. Prediction, the results show that most of these derivatives have membrane permeability Both are higher than paclitaxel, and their oral bioavailability can be expected to be increased to varying degrees.
- alkyl refers to a group consisting only of carbon atoms and hydrogen atoms and having no degree of unsaturation (for example, a double bond, a triple bond or a ring), which covers various possible geometrical differences. a group and a stereoisomer. This group is attached to the rest of the molecule by a single bond.
- C1-C6 alkyl group as used in the present invention means an alkyl group as defined above having 1 to 6 carbon atoms, and as a non-limiting example of a C1-C6 alkyl group, the following linear or branched chain may be mentioned.
- alkenyl refers to a group formed in the case where one or more double bonds are present in the above alkyl group (except for a methyl group).
- C1-C6 alkenyl means an alkenyl group as defined above having 1 to 6 carbon atoms.
- alkynyl refers to a group formed in the case where one or more triple bonds are present in the above alkyl group (except for a methyl group).
- C1-C6 alkynyl refers to an alkynyl group as defined above having 1 to 6 carbon atoms.
- hydrocarbyl group as used in the present invention means a group consisting only of a carbon atom and a hydrogen atom
- substituted hydrocarbyl group means an alkyl group, an alkenyl group or an alkynyl group or the like as defined above having a substituent.
- the substituent may be a hydroxyl group, an amino group or the like.
- heterocyclyl refers to an aromatic 5-14 membered ring system or a non-aromatic 3-15 membered ring system composed of a carbon atom and a hetero atom independently selected from N, O or S.
- the aromatic ring system may be monocyclic, bicyclic, or polycyclic, wherein the bicyclic ring and the polycyclic ring may be formed from a single ring by a single bond or a condensed form.
- heteroaryl groups the following groups may be mentioned: oxazolyl, isoxazolyl, imidazolyl, furyl, fluorenyl, isodecyl, pyrrolyl, triazolyl, triazinyl , tetrazolyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, Benzothiophenyl, benzopyranyl, oxazolyl, quinolyl, isoquinolinyl, quinazolinyl, porphyrinyl, naphthyridyl, pteridinyl, fluorenyl, quinoxalinyl, thia Diazolyl, pyridazinyl, a
- the non-aromatic ring system may be monocyclic, bicyclic or polycyclic, or may be a fused ring, a bridged ring, a spiro ring, and may optionally contain one or more double bonds.
- a heterocyclic group the following groups may be mentioned: aza Base, acridinyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholyl, decahydroiso Quinolinyl, indanyl, porphyrin, isoindolyl, isochroman, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazole Alkyl, oxadiazolyl, 2-oxopiperrazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoaza Base,
- aryl refers to an aromatic ring system consisting of at least 6 carbon atoms, which ring system may be monocyclic, bicyclic or polycyclic, wherein the bicyclic and polycyclic rings may be bonded by a single ring through a single bond. Formed in a fused manner.
- aryl group the following groups may be mentioned: phenyl, naphthyl, anthryl, phenanthryl, anthracenyl, fluorenyl, fluorenyl, fluorenyl, fluorenyl, benzofluorenyl, Triphenylene, Base, biphenyl, binaphthyl and the like.
- substituted aryl group as used in the present invention means an aryl group as defined above having a substituent.
- the substituent may be an alkyl group, an alkenyl group, an alkynyl group, a hydroxyl group, an amino group or the like.
- the taxane compound of the present invention has a structure of the following formula I:
- R 1 is -COR 6 , -COOR 6 , -CONR 7a R 7b ;
- R 2 is C1-C6 alkyl, C1-C6 alkenyl, substituted hydrocarbyl, heterocyclyl, aryl or substituted aryl;
- R 3 is -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b ;
- R 4 is -OR 6 , -OCOOR 6 , -OCOSR 6 , -OCONR 7a R 7b , H, OH;
- R 6 is a C1-C6 alkyl group, a C1-C6 alkenyl group, a C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and each of R 7a and R 7b is a hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group. ;
- R 1 is benzoyl, tert-butyloxycarbonyl, N,N'-dimethylformyl;
- R 2 is a phenyl group
- R 3 is -OMe, -OCOOCH 3 , -OCON(CH 3 ) 2 , -OCOSC 2 H 5 ;
- R 4 is -OMe, -OCOOCH 3 , -OCON(CH 3 ) 2 , -OCOSC 2 H 5 , H, OH.
- taxane compound of the present invention is selected from the group consisting of compounds having the following structure:
- the compounds of the general formula (I) of the present invention also include all isomeric forms of these compounds and a mixture of isomers.
- the compound of formula (I) of the present invention may be formed into a pharmaceutically acceptable non-toxic pharmaceutically acceptable salt, if necessary.
- the compounds of the formula (I) of the present invention may also exist in the form of solvates (e.g., hydrates), and therefore, such solvates (e.g., hydrates) are also included in the compounds of the present invention.
- solvates e.g., hydrates
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the formula (I) as defined above, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient, and a taxane compound of the present invention, a pharmaceutically acceptable salt thereof or The use of a pharmaceutical composition whose solvate is an active ingredient for the preparation of an oral antitumor drug.
- the weight ratio of the compound of the present invention in the pharmaceutical composition is from 0.01% to 99.99%, and the balance is a pharmaceutically acceptable carrier.
- the pharmaceutical compositions are in the form of a pharmaceutically acceptable preparation.
- Medicinal preparations are tablets, capsules, granules, pills, powders, ointments, suspensions, injections, powders, suppositories, creams, drops, or patches.
- the tablet is a sugar-coated tablet, a film-coated tablet, an enteric coated tablet or a sustained-release tablet
- the capsule is a hard capsule
- the powder injection is a lyophilized powder injection.
- each dose refers to each preparation unit, such as each tablet of a tablet, capsule
- each capsule can also be referred to each dose (eg, 100 mg each time).
- the pharmaceutical composition of the present invention can be used in the preparation of solid or semisolid pharmaceutical preparations in the form of powders, tablets, dispersible powders, capsules, cachets, suppositories and ointments.
- the solid carrier which can be used is preferably one or more selected from the group consisting of a diluent, a flavoring agent, a solubilizer, a lubricant, a suspending agent, a binder, a swelling agent and the like, or may be an encapsulating substance.
- a diluent preferably one or more selected from the group consisting of a diluent, a flavoring agent, a solubilizer, a lubricant, a suspending agent, a binder, a swelling agent and the like, or may be an encapsulating substance.
- 5 to 70% by weight of the micronized active ingredient is contained in the carrier.
- Suitable solid carriers include magnesium carbonate, magnesium stearate, talc, sucrose, lactose, pectin, dextrin, starch, gelatin, methylcellulose, sodium carboxymethylcellulose, low boiling waxes, cocoa butter, and the like. Since tablets, powders, cachets, and capsules are easy to administer, they represent the most advantageous oral solid preparations.
- Liquid preparations of the invention include solutions, suspensions and emulsions.
- an injection preparation for parenteral administration may be in the form of water or a water-propylene glycol solution for adjusting its isotonicity, pH, and the like to be suitable for physiological conditions of a living body.
- Liquid preparations can also be prepared in the form of solutions in polyethylene glycol, aqueous solutions.
- An oral aqueous solution can be prepared by dissolving the active ingredient in water, followed by the addition of a suitable amount of coloring, flavoring, stabilizing and thickening agents.
- the micronized active ingredient can be dispersed in viscous materials such as natural and synthetic gums, methylcellulose, sodium carboxymethylcellulose, and other known suspending agents to prepare aqueous suspensions suitable for oral administration.
- Dosage unit form of the formulation refers to physically discrete units suitable as a single dose, each unit containing a calculated predetermined amount of active ingredient that produces the desired therapeutic effect.
- Such dosage unit forms can be in the form of a package such as a tablet, a capsule or a powder in a vial or vial, or an ointment, gel or cream in a tube or vial.
- the amount of active ingredient contained in the dosage unit form may vary, it will generally be in the range of from 1 mg to 1000 mg, depending on the potency of the active ingredient selected.
- the dose to be administered may vary depending on the needs of the patient, depending on the condition, the selected compound, and the like.
- a method for preparing a taxane compound of the present invention comprising:
- Step 1 Synthesis of the taxane core moiety: 10-deacetylbaccatin III was used as the starting material.
- the C7 and C10 hydroxyl groups were selectively protected by a substituent, and then the C13 hydroxyl group was oxidized to a ketone carbonyl group.
- CDI N,N'-carbonyldiimidazole
- the carbonate structure finally, by CBS reduction method, highly stereoselectively reduces the C13 ketone carbonyl group to the hydroxyl group of the ⁇ configuration, and obtains the taxane core moiety.
- Step 2 Synthesis of 5-membered ring oxazolidine acid side chain precursor: After a series of upper protecting groups, addition condensation, acid hydrolysis, aldol condensation, catalytic hydrogenation, etc., a 5-membered oxazolidine is prepared. Acid side chain precursor;
- Step 3 Synthesis of a taxane derivative: the five-membered cyclic oxazolidine acid side chain precursor is esterified and docked with the taxane-based parent core portion, and subjected to acid hydrolysis and deprotection to form a series of Taxane derivatives.
- the preparation method of the present invention comprises the following steps:
- Step 1 Synthesis of the taxane core moiety: 10-deacetylbaccatin III was used as the starting material.
- the C7 and C10 hydroxyl groups were selectively protected by a substituent, and then the C13 hydroxyl group was oxidized to a ketone carbonyl group.
- CDI N,N'-carbonyldiimidazole
- the carbonate structure finally, by CBS reduction method, highly stereoselectively reduces the C13 ketone carbonyl group to the hydroxyl group of the ⁇ configuration, and obtains the taxane core moiety.
- Step 2 Synthesis of 5-membered ring oxazolidine acid side chain precursor: using glycolic acid as raw material, followed by benzyl protection and tert-butylcarbonyl (Boc group) protection to form Boc-protected benzyl glycolate;
- the substituted aldehyde is separately condensed with (S R )-tert-butyl sulfenamide to form the corresponding enamine compound.
- the Boc-protected benzyl glycolate and the enamine compound are added under the action of a lithium salt, and then subjected to acid hydrolysis to obtain a chiral intermediate, which is catalyzed by p-toluenesulfonic acid pyridinium salt (PPTS).
- PPTS p-toluenesulfonic acid pyridinium salt
- 1,1'-(dimethoxymethyl)-p-methoxybenzene is subjected to condensation reaction of aldol, and the amino group in the resulting compound is substituted with a different substituent, and finally subjected to catalytic hydrogenation to obtain a five-membered ring oxazole.
- Alkanoic acid side chain precursor The specific steps are as follows:
- Step 3 Synthesis of taxane derivatives: esterification of the five-membered ring oxazolidine side chain precursor with the taxane core moiety, and deprotection by acid hydrolysis to form a series of taxanes derivative.
- step 1 the substituent protection is carried out for the hydroxyl groups at the C7 and C10 positions:
- R 3 and R 4 are -OR 6
- the reaction involved is as follows: firstly, with tetrahydrofuran or dichloromethane as a solvent, at room temperature to 0 ° C, pyridine as a base, with p-toluenesulfonyl chloride The reaction produces p-toluenesulfonyl ester and reacts with Grignard reagent to form the corresponding ether-OR 6 ;
- R 3 and R 4 are -OCOSR 6
- the reaction involved is: reacting with N,N'-carbonyldiimidazole (CDI) at room temperature in tetrahydrofuran as a solvent, and the resulting product is further reacted with a mercaptan. Substitution reaction;
- the specific step of stereoselective reduction of the C13 ketone carbonyl group by the CBS reduction method is as follows: at room temperature to -70 ° C, in anhydrous tetrahydrofuran, dry dichloromethane or alcohol as a solvent, R)-2-methyloxazole borane as a catalyst, borane as a reducing agent, stereoselective reduction of C13-oxo to C13- ⁇ -OH;
- the different substituted aldehydes include: a C1-C6 hydrocarbyl aldehyde, a C1-C6 substituted hydrocarbyl aldehyde, an aromatic aldehyde, a substituted aromatic aldehyde, an aromatic aldehyde, etc.; when the amino group on the chiral intermediate is substituted
- the reaction involved is carried out under basic conditions using tetrahydrofuran, dichloromethane or dioxane as a solvent, at room temperature to -70 ° C, with the corresponding acid chloride; the catalytic hydrogenation reaction is palladium Carbon or palladium hydroxide is used as a catalyst, hydrogen is added under normal pressure or under pressure, and it is carried out in a solvent such as alcohol, tetrahydrofuran or dichloromethane.
- step 1 the substituent protection is carried out for the hydroxyl groups at the C7 and C10 positions:
- R 3 , R 4 is -OR 6 , preferably using dichloromethane as a solvent, the temperature is 0 ° C, the Grignard reagent is R 6 MgBr;
- the basic condition is preferably lithium hexamethyldisilazide as a base, and the temperature is preferably -40 ° C, and the acid chloride includes R 6 OCOCl, R 7a R 7b NCOCl;
- the specific step of stereoselective reduction of the C13 ketone carbonyl group by the CBS reduction method is preferably carried out under anhydrous air temperature using tetrahydrofuran as a solvent;
- the reaction involved in the substitution of the amino group on the intermediate is preferably lithium hexamethyldisilazide as a base and tetrahydrofuran as a solvent, and the temperature is preferably -40 ° C, and the acid chloride includes R 6 . COCl, R 6 OCOCl, R 7a R 7b NCOCl; the catalytic hydrogenation reaction, preferably using palladium hydroxide as a catalyst, is carried out under hydrogen at 20 psi, preferably in an alcoholic solution.
- the taxane compound of the present invention has oral antitumor activity, and the beneficial effects of the present invention are explained below by experimental data.
- MTT assay was used to investigate the 1,14-carbonate baccatin III taxane derivatives against 16 cancer cell lines (including MCF-7, MDA-MB-436 breast cancer cells; A549).
- 16 cancer cell lines including MCF-7, MDA-MB-436 breast cancer cells; A549).
- NCI-H460 non-small cell lung cancer A2780 ovarian cancer; A375, B16 melanoma; HCT116, HT-29 colon cancer; Hela cervical cancer; HL-60, K562 Leukemia; LNCaP, Du145 prostate cancer; LN-18, BGC-823 gastric cancer
- Proliferation inhibition rate at 1 ⁇ M concentration the experimental results are shown in Table 1.
- the IC 50 value of the positive control drug paclitaxel was 7.05 nM
- the IC 50 value of the series of taxane derivatives containing the 1,14-carbonate baccatin III structure of the present invention and paclitaxel Quite, basically kept in an order of magnitude, some derivatives have IC 50 values better than paclitaxel. It can be seen that the in vitro cell viability of the series of derivatives of the present invention remains unchanged or even increased compared to paclitaxel.
- the bidirectional transport of target compounds from the apical (AP) to the basolateral (BL) and from the BL side to the AP side was studied using the Caco-2 monolayer cell model of human colonic adenocarcinoma cell line. Quantitative analysis by high performance liquid chromatography, calculation of transport parameters and apparent permeability coefficient (Papp) and efflux ratio, using paclitaxel as a positive control, P-gp acting as a substrate for red mold The reference substance is used to predict the in vivo oral bioavailability of such taxane derivatives and the affinity with P-gp.
- N/A not detected in existing detection methods
- N/A not detected in existing detection methods
- the inventors selected 10 compounds from these 21 taxane derivatives to evaluate their bidirectional transport, and the results are shown in Table 5. As can be seen from the efflux rate, the present invention is relative to paclitaxel. The derivatives have alleviated the efflux situation to varying degrees, and it is predicted that the oral absorption in the body will be correspondingly improved.
- the compound PCMI-08 was synthesized and tested according to the method of the present invention.
- the internal standard paclitaxel was purchased from the China National Institute for the Control of Pharmaceutical and Biological Products, the chromatographic acetonitrile was purchased from Sigma-Aldrich, the Tween 80 and the ethyl acetate were purchased from the Aladdin reagent. the company.
- Male S.D. rats were purchased from Beijing Vital Lihua Company and kept in animal houses for two weeks.
- PCMI-08 200 mg was dissolved in 4 ml of a mixture of Tween 80 and absolute ethanol (1:1) to prepare a 50 mg/ml original solution, and physiological saline was added thereto to adjust to a suitable concentration.
- Twelve male SD rats (300 g) were taken and fasted the night before. They were divided into two groups, one group (5 mg/kg) and the other group (60 mg/kg). Blood was taken at 0 min, 5 min, 10 min, 20 min, 40 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h.
- the oral group was at 5 min, 15 min, 30 min, 45 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h. Blood was taken at 24 hours. After the plasma was centrifuged at 4500 rpm for 10 min, the supernatant serum was transferred to the corresponding EP tube and stored in a refrigerator at -40 ° C for storage.
- Agilent 1100series high performance liquid chromatography configuration Agilent G1313A automatic sample introduction device, using 150mm ⁇ 2.1mm C18 Thermo column (particle size 3 ⁇ m) reversed phase column, detection wavelength is 230nm, column temperature 30 ° C, mobile phase is acetonitrile / water (7:3 ), the flow rate is 0.2ml/min, the injection volume is 20 ⁇ l, the mass spectrometer model is Thermo Finnigan TSQ Quantum triple quadrupole, and the electrospray ion source (ESI) is configured to analyze the parameters of the sample in positive ion mode.
- ESI electrospray ion source
- spray chamber voltage 4.0 kv
- capillary heating temperature 350 ° C
- shielding gas (nitrogen) 20 psi
- auxiliary gas (nitrogen) 5 psi
- collision gas (argon) pressure 1.5 mm Torr
- collision energy CA is 17 eV
- FA and IFA are 19 eV
- IS is 15 eV.
- Paclitaxel was selected as the internal standard, and the retention time was 3.07 min, and the retention time of PCMI-08 was 5.13 min.
- the detection conditions of the mass spectrometer for PCMI-08 were set to: 957 ⁇ 901 m/z. Paclitaxel was used as an internal standard, and the detection conditions were: 876 ⁇ 308 m/z.
- the standard curve of PCMI-08 has a concentration range of 5-10,000 ng/ml ( ⁇ 2 >0.99) and a minimum detection limit of 5 ng/ml.
- the intravenous and oral drug time curves of the compound PCMI-08 are shown in Figure 1.
- the relevant pharmacokinetic parameters are shown in the following table.
- the half-life of PCMI-08 is relatively long, generally 10 h, and the average residence time is also extended accordingly, reaching more than 10 h, and its absolute oral bioavailability (F%) is as high as 65.8%.
- the oral bioavailability of the compound in animals is greatly improved relative to the reported absolute oral bioavailability of paclitaxel of less than 6%.
- the Boc-protected benzyl glycolate (32.5 g, 0.12 mol) was dissolved in 15 ml of tetrahydrofuran, and LHMDS (120 ml, 0.12 mol) was slowly added dropwise to the reaction solution at -70 ° C. After the addition was completed, the mixture was stirred. After 0.5 h, a solution of N-tert-butylsulfinylbenzylamine in THF (5.02 g, 0.024 mol in 8 ml of THF) was slowly added dropwise to the reaction mixture, and the reaction was stopped after 4 hours.
- reaction solution was poured into 50 ml of a saturated aqueous solution of ammonium chloride and extracted with ethyl acetate (30 ml ⁇ 3). 1) Isolated to give a white solid (5.25 g, 46%).
- the product of the previous step (5.25 g, 0.011 mol) was dissolved in 20 ml of 2N HCl / EtOAc solution and was reacted for 10h at room temperature. After the reaction was completed, it was concentrated, and the concentrate was extracted with dichloromethane / water (50ml / 100ml). The aqueous phase was extracted with dichloromethane, and the pH of the aqueous phase was adjusted to 9 to 10 with 28% aqueous ammonia. The mixture was extracted with dichloromethane (20 ml ⁇ 3), and the organic phase was combined. g, 95.7%).
- PCMI-01 mp: 242 ⁇ 243 ° C;
- PCMI-02 mp: 234 ⁇ 235 ° C;
- Example 1 In addition to the difference in g steps, the preparation method of (4S,5R)-3-dimethylaminoformyl-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic acid
- the procedure shown in Example 1 is substantially the same, and the rest of the steps are as described in the reaction of Example 1.
- step 2) 7,10-methoxy-1,14-carbonate-bakacaine III and the preparation process of PCMI-03 in step 3) and 2) and 3) in Example 1
- step 2) and step 3) in Example 1 For the same, see step 2) and step 3) in Example 1.
- the final product purity is above 95%.
- PCMI-03 mp: 205 ⁇ 206 ° C;
- step 2) 7,10-methoxy-1,14-carbonate-bakacaine III and the preparation process of PCMI-04 in step 3) and 2) and 3) in example 1.
- step 2) and step 3) in Example 1.
- the purity of the final product is above 95%.
- PCMI-04 mp: 244 ⁇ 245 ° C;
- step 2) 7,10-methoxy-1,14-carbonate-bakaciting III and the preparation process of PCMI-05 in step 3) and 2) and 3) in Example 1
- step 2) and step 3) in Example 1 For the same, see step 2) and step 3) in Example 1.
- the purity of the final product is above 95%.
- PCMI-05 mp: 237 ⁇ 238 ° C;
- PCMI-06 mp: 233 ⁇ 235 ° C;
- PCMI-07 mp: 226 ⁇ 227 ° C;
- PCMI-08 mp: 246 ⁇ 247 ° C;
- PCMI-09 mp: 241 ⁇ 242 ° C;
- PCMI-10 mp: 236 ⁇ 237 ° C;
- PCMI-11 mp: 241 ⁇ 242 ° C;
- PCMI-12 mp: 231 ⁇ 232 ° C;
- PCMI-13 mp: 215 ⁇ 216 ° C;
- PCMI-14 mp: 236 ⁇ 237 ° C;
- PCMI-15 mp: 231 ⁇ 232 ° C;
- PCMI-16 mp: 227 ⁇ 228 ° C;
- PCMI-17 mp: 233 ⁇ 234 ° C;
- IR 3411, 2979, 2933, 1820, 1731, 1712, 1490, 1367, 1259, 1163, 1085, 713.
- PCMI-18 mp: 235 ⁇ 236 ° C;
- PCMI-20 mp: 229 ⁇ 230 ° C;
- PCMI-21 mp: 238 ⁇ 239 ° C;
Abstract
Description
Claims (12)
- 如权利要求1-3中任一项所述的紫杉烷类化合物,其中,所述紫杉烷类化合物还包括这些化合物的所有异构体形式和异构体的混合物形式。
- 如权利要求1-3中任一项所述的紫杉烷类化合物,所述化合物形成了药学上可接受的非毒性药用盐。
- 如权利要求1-3中任一项所述的紫杉烷类化合物,所述化合物以溶剂化物的形式存在。
- 一种抗肿瘤药物组合物,所述组合物含有权利要求1-6中任一项所述的式(I)化合物、其药用盐或其溶剂化物作为活性成分。
- 如权利要求7所述的药物组合物,其中,所述的式(I)化合物、其药用盐或其溶剂化物在所述药物组合物中的重量比为0.01%~99.99%,其余为药学上可接受的载体。
- 如权利要求1-6中任一项所述的紫杉烷类化合物、其药用盐、或其溶剂化物以及如权利要求7或8所述的药物组合物在制备口服抗肿瘤药物中的用途。
- 如权利要求1-3中任一项所述的紫杉烷类化合物的制备方法,其特征在于,所述方法包括以下步骤:步骤1:紫杉烷类母核部分的合成:以10-去乙酰基巴卡亭III为原料,首先对C7、C10位羟基进行选择性地取代基保护,然后将C13位羟基氧化为酮羰基,再利用N-(磺酰基)氧杂吖丙啶,高度立体选择性地在C14位引入β构型的羟基,在N,N’-羰基二咪唑的作用下形成1,14-碳 酸酯结构,最后通过CBS还原法,高度立体选择性地将C13位酮羰基还原为α构型的羟基,得到紫杉烷类母核部分;步骤2:五元环噁唑烷酸侧链前体的合成:采用乙醇酸先后经过苄基保护,Boc基保护生成Boc保护的乙醇酸苄酯;不同的取代醛分别与(SR)-叔丁基亚磺酰胺缩合,生成相应的烯胺化合物;Boc保护的乙醇酸苄酯和烯胺化合物在锂盐的作用下进行加成,再经酸水解,得到手性中间体,该中间体在对甲苯磺酸吡啶盐的催化作用下与1,1’-(二甲氧基甲基)对甲氧基苯发生羟醛缩合反应,生成的化合物中的氨基再经不同的取代基进行取代,最后经过催化氢化得到五元环噁唑烷酸侧链前体;步骤3:紫杉烷类衍生物的合成:将所述五元环噁唑烷酸侧链前体与所述紫杉烷类母核部分进行酯化对接,经过酸水解脱保护生成一系列的紫杉烷类衍生物。
- 如权利要求10所述的紫杉烷类化合物的制备方法,其特征在于,步骤1中,所述对C7、C10位羟基进行取代基保护:①当R3、R4为-OR6时,所涉及的反应为:首先在四氢呋喃或二氯甲烷作为溶剂,室温到0℃的条件下,吡啶作为碱的作用下,与对甲苯磺酰氯反应,生成对甲苯磺酰酯,再与格氏试剂反应,生成相应的醚-OR6;②当R3、R4为-OCOOR6、-OCONR7aR7b时,所涉及的反应为:在碱性条件下,以四氢呋喃作为溶剂,在室温至-70℃的温度下,与相应的酰氯进行反应;③当R3、R4为-OCOSR6时,所涉及的反应为:四氢呋喃作为溶剂,室温下,与N,N’-羰基二咪唑进行反应,生成的产物再与硫醇进行取代反应;步骤1中,所述通过CBS还原法对C13位酮羰基进行立体选择性还原的具体步骤为:室温至-70℃的温度下,以无水四氢呋喃、干燥二氯甲烷或醇类作为溶剂,(R)-2-甲基噁唑硼烷作为催化剂,硼烷作为还原剂的条件下,将C13-oxo立体选择性的还原为C13α-OH;步骤2中,所述不同的取代醛包括:C1-C6烃醛、C1-C6取代烃基醛、芳香醛、取代芳香醛、芳杂醛;所述对得到的手性中间体上的氨基进行取代时所涉及的反应是在碱性条件下,以四氢呋喃、二氯甲烷或二氧六环作为溶剂,室温至-70℃的温度下,与相应的酰氯进行反应;所述的催化氢化反应是以钯碳或氢氧化钯为催化剂,常压或加压的条件下加入氢气,在醇、四氢呋喃或二氯甲烷溶剂中进行。
- 如权利要求11所述的紫杉烷类化合物的制备方法,其特征在于:步骤1中,所述对于C7、C10位羟基进行取代基保护:①当R3、R4为-OR6时,以二氯甲烷作为溶剂,温度为0℃,所述格氏试剂包括R6MgBr;②当R3、R4为-OCOOR6、-OCONR7aR7b时,碱性条件以六甲基二硅基氨基锂作为碱,温度-40℃,所述酰氯包括R6OCOCl、R7aR7bNCOCl;③当R3、R4为-OCOSR6时,所述硫醇包括R6SH;步骤1中,所述通过CBS还原法对C13位酮羰基进行立体选择性还原的具体步骤中,在 室温的条件下,以无水四氢呋喃作为溶剂进行;步骤2中,对于中间体上的氨基进行取代时所涉及的反应,以六甲基二硅基氨基锂作为碱,四氢呋喃作为溶剂,温度-40℃,所述酰氯包括R6COCl、R6OCOCl、R7aR7bNCOCl;所述催化氢化反应,以氢氧化钯作为催化剂,20psi的条件下加入氢气,在醇溶液中进行。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2931366A CA2931366C (en) | 2013-11-22 | 2014-11-21 | Taxane compound, and preparation method and use thereof |
JP2016554787A JP6573900B2 (ja) | 2013-11-22 | 2014-11-21 | タキサン化合物およびその製造方法およびその使用 |
AU2014352372A AU2014352372B2 (en) | 2013-11-22 | 2014-11-21 | Taxane compound, and preparation method and use thereof |
KR1020167016613A KR20160087899A (ko) | 2013-11-22 | 2014-11-21 | 탁산(Taxane) 화합물 및 제조방법과 그 이용 |
US15/039,271 US9890175B2 (en) | 2013-11-22 | 2014-11-21 | Taxane compound, and preparation method and use thereof |
RU2016124631A RU2686459C1 (ru) | 2013-11-22 | 2014-11-21 | Таксановое соединение, а также способ его получения и его применение |
DK14863167.4T DK3072896T5 (da) | 2013-11-22 | 2014-11-21 | Taxanforbindelse og fremgangsmåde til fremstilling heraf og dennes anvendelse |
EP14863167.4A EP3072896B1 (en) | 2013-11-22 | 2014-11-21 | Taxane compound, and preparation method and use thereof |
ZA2016/03990A ZA201603990B (en) | 2013-11-22 | 2016-06-13 | Taxane compound, and preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310594994.XA CN104650109B (zh) | 2013-11-22 | 2013-11-22 | 紫杉烷类化合物 |
CN201310594994.X | 2013-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015074606A1 true WO2015074606A1 (zh) | 2015-05-28 |
Family
ID=53178985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2014/091911 WO2015074606A1 (zh) | 2013-11-22 | 2014-11-21 | 紫杉烷类化合物、其制备方法和用途 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9890175B2 (zh) |
EP (1) | EP3072896B1 (zh) |
JP (1) | JP6573900B2 (zh) |
KR (1) | KR20160087899A (zh) |
CN (1) | CN104650109B (zh) |
AU (1) | AU2014352372B2 (zh) |
CA (1) | CA2931366C (zh) |
DK (1) | DK3072896T5 (zh) |
RU (1) | RU2686459C1 (zh) |
WO (1) | WO2015074606A1 (zh) |
ZA (1) | ZA201603990B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107056767B (zh) * | 2015-12-04 | 2022-07-15 | 江苏恩华络康药物研发有限公司 | 用于制备水溶性紫杉烷类衍生物的方法及中间体 |
CN110143934B (zh) * | 2018-08-29 | 2023-03-28 | 牡丹江师范学院 | 一种含氟紫杉烷类化合物及其制备方法与应用 |
CN110590793A (zh) * | 2019-08-30 | 2019-12-20 | 浙江工业大学 | 一种2,4-二苯基吡啶并[3,2-c]香豆素的合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1123547A (zh) * | 1993-03-26 | 1996-05-29 | 纽约州州立大学研究基金会 | 抗肿瘤化合物、药物组合物、其制备方法以及其用于治疗的方法 |
EP0747372A1 (en) * | 1995-06-06 | 1996-12-11 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-beta-hydroxy-10 deacetybaccatin III |
CN1359384A (zh) * | 1999-07-06 | 2002-07-17 | 因迪纳有限公司 | 紫杉烷衍生物及其制备方法 |
CN1478091A (zh) * | 2000-11-28 | 2004-02-25 | 制备紫杉烷衍生物的方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2698363B1 (fr) * | 1992-11-23 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions qui les contiennent. |
IT1275435B (it) * | 1995-05-19 | 1997-08-07 | Indena Spa | Derivati della 10-desacetil-14beta-idrossibaccatina iii,loro metodo di preparazione e formulazioni che li contengono |
DK1221445T3 (da) * | 1999-10-15 | 2008-11-24 | Daiichi Sankyo Co Ltd | Pentacykliske taxanforbindelser |
CN1960721A (zh) * | 2004-03-05 | 2007-05-09 | 佛罗里达州立大学研究基金有限公司 | C7乳酰氧基取代的紫杉烷类 |
CN1923189A (zh) * | 2005-08-30 | 2007-03-07 | 孔庆忠 | 一种紫杉碱类抗癌药物的缓释注射剂 |
EP2080764B1 (en) * | 2008-01-18 | 2012-08-22 | INDENA S.p.A. | Solid forms of ortataxel |
EP2080763A1 (en) * | 2008-01-18 | 2009-07-22 | INDENA S.p.A. | Crystalline form I of ortataxel |
CN101353333B (zh) * | 2008-09-08 | 2010-08-11 | 上海大学 | 10-去乙酰基-9(r)-氢化-1-去氧紫杉醇类似物及其制备方法 |
AU2012364858A1 (en) * | 2011-04-07 | 2013-11-21 | Arbor Therapeutics, LLC | Taxane and abeo-taxane analogs |
-
2013
- 2013-11-22 CN CN201310594994.XA patent/CN104650109B/zh active Active
-
2014
- 2014-11-21 WO PCT/CN2014/091911 patent/WO2015074606A1/zh active Application Filing
- 2014-11-21 JP JP2016554787A patent/JP6573900B2/ja active Active
- 2014-11-21 KR KR1020167016613A patent/KR20160087899A/ko not_active Application Discontinuation
- 2014-11-21 RU RU2016124631A patent/RU2686459C1/ru active
- 2014-11-21 AU AU2014352372A patent/AU2014352372B2/en active Active
- 2014-11-21 EP EP14863167.4A patent/EP3072896B1/en active Active
- 2014-11-21 CA CA2931366A patent/CA2931366C/en active Active
- 2014-11-21 DK DK14863167.4T patent/DK3072896T5/da active
- 2014-11-21 US US15/039,271 patent/US9890175B2/en active Active
-
2016
- 2016-06-13 ZA ZA2016/03990A patent/ZA201603990B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1123547A (zh) * | 1993-03-26 | 1996-05-29 | 纽约州州立大学研究基金会 | 抗肿瘤化合物、药物组合物、其制备方法以及其用于治疗的方法 |
EP0747372A1 (en) * | 1995-06-06 | 1996-12-11 | Dr. Reddy's Research Foundation | Taxane derivatives from 14-beta-hydroxy-10 deacetybaccatin III |
CN1359384A (zh) * | 1999-07-06 | 2002-07-17 | 因迪纳有限公司 | 紫杉烷衍生物及其制备方法 |
CN1478091A (zh) * | 2000-11-28 | 2004-02-25 | 制备紫杉烷衍生物的方法 |
Non-Patent Citations (5)
Title |
---|
APPENDINO, G. ET AL., J. CHEM. SOC., PERKINS TRANS, vol. 1, 1992, pages 2925 - 2929 |
H. GELDERBLOM ET AL., EUR. J. CANCER, vol. 37, no. 13, 2001, pages 1590 - 1598 |
R. B. WEISS ET AL., J. CLIN. ONCOL., vol. 8, no. 7, 1990, pages 1263 - 1268 |
TEN TIJE AJ ET AL., CLIN PHARMACOKINET, vol. 42, 2003, pages 655 - 685 |
VAN ZUYLEN L ET AL., INVEST NEW DRUGS, vol. 19, 2001, pages 125 - 141 |
Also Published As
Publication number | Publication date |
---|---|
RU2016124631A (ru) | 2017-12-27 |
CA2931366C (en) | 2019-09-24 |
RU2686459C1 (ru) | 2019-04-26 |
EP3072896B1 (en) | 2021-01-06 |
DK3072896T3 (da) | 2021-04-06 |
JP2016539187A (ja) | 2016-12-15 |
US20160340365A1 (en) | 2016-11-24 |
US9890175B2 (en) | 2018-02-13 |
ZA201603990B (en) | 2019-04-24 |
CN104650109B (zh) | 2019-01-01 |
AU2014352372A1 (en) | 2016-06-16 |
CN104650109A (zh) | 2015-05-27 |
KR20160087899A (ko) | 2016-07-22 |
DK3072896T5 (da) | 2021-05-31 |
CA2931366A1 (en) | 2015-05-28 |
EP3072896A4 (en) | 2017-09-06 |
JP6573900B2 (ja) | 2019-09-11 |
AU2014352372B2 (en) | 2018-08-30 |
EP3072896A1 (en) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021129820A1 (zh) | 含螺环的喹唑啉化合物 | |
JP2022502385A (ja) | Shp2の活性を阻害するための化合物の製造方法 | |
JP2012509351A (ja) | 有機化合物のフッ素化 | |
JP5221131B2 (ja) | ベンゼノイドアンサマイシン誘導体 | |
WO2023280136A1 (zh) | 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用 | |
WO2015074606A1 (zh) | 紫杉烷类化合物、其制备方法和用途 | |
EP2283023A2 (en) | Bryostatin analogues and methods of making and using thereof | |
CN111196790B (zh) | 新型紫杉烷类衍生物及其药物组合物和用途 | |
CN114437109A (zh) | 一种十字孢碱卤代衍生物及其制备方法与应用 | |
WO2015074605A1 (zh) | 一种紫杉烷类化合物、其制备方法和用途 | |
WO2023193563A1 (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
WO2015096553A1 (zh) | 抗多药耐药紫杉烷类抗肿瘤化合物及其制备方法 | |
CN112225730A (zh) | 一种稠环化合物的晶型、其组合物、制备方法及其应用 | |
CN109748891B (zh) | 多西他赛衍生物和其药物组合物与用途 | |
US8697892B2 (en) | Taxane compounds, compositions and methods | |
CN118001423A (zh) | 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用 | |
WO2023227006A1 (zh) | 一类二氘代喜树碱衍生物及制备方法 | |
Yang | Syntheses and Bioactivities of Targeted and Conformationally Restrained Paclitaxel and Discodermolide Analogs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14863167 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016554787 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2931366 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15039271 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014863167 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014863167 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014352372 Country of ref document: AU Date of ref document: 20141121 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167016613 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016124631 Country of ref document: RU Kind code of ref document: A |